SML3743
Tegobuvir
≥98% (HPLC)
别名:
GS 9190, 5-({6-[2,4-Bis(trifluoromethyl)phenyl]pyridazin-3-yl}methyl)-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine, 5-[[6-[2,4-Bis(trifluoromethyl)phenyl]-3-pyridazinyl]methyl]-2-(2-fluorophenyl)-5H-imidazo[4,5-c]pyridine, GS 333126, GS-333126, GS-9190, GS333126, GS9190, TGV
登录 查看组织和合同定价。
选择规格
变更视图
关于此项目
经验公式（希尔记法）:
C25H14F7N5
化学文摘社编号:
分子量:
517.40
UNSPSC Code:
51111800
NACRES:
NA.77
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality Segment
assay
≥98% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 2 mg/mL, clear
storage temp.
-10 to -25°C
SMILES string
FC(F)(F)c1c(ccc(c1)C(F)(F)F)c2nnc(cc2)C[n]3cc4nc(nc4cc3)c5c(cccc5)F
InChI
1S/C25H14F7N5/c26-19-4-2-1-3-17(19)23-33-21-9-10-37(13-22(21)34-23)12-15-6-8-20(36-35-15)16-7-5-14(24(27,28)29)11-18(16)25(30,31)32/h1-11,13H,12H2
InChI key
XBEQSQDCBSKCHJ-UHFFFAOYSA-N
Biochem/physiol Actions
Orally active, non-cytotoxic, potent and genotype 1 replicons-selective non-nucleoside inhibitor (NNI) against hepatitis C virus (HCV).
Tegobuvir (GS-9190; TGV) is an orally active, non-cytotoxic imidazopyridine that, upon CYP-mediated intracellular activation, forms a glutathione conjugate that acts as a covalent, potent and genotype 1 replicons-selective non-nucleoside inhibitor (NNI) against hepatitis C virus (HCV) NS5B RNA-dependent RNA polymerase (IC50 = 0.8 nM/1b, 13.8 nM/1a, 21.9 μM/2a, >50 μM/1a; IC50 >100 nM against 2b, 3a, 4a, 5a, and 6a). When combined with suboptimal concentrations of other direct acting antivirals (DAAs) in cultures, tegobuvir (6-30 nM) is highly effective in curing cells from HCV replicon and in delaying or preventing the development of resistance against other DAAs.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable